Polyamine transport selective therapeutic agents with enhanced stability

US9926260B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9926260-B2
Application numberUS-201615138531-A
CountryUS
Kind codeB2
Filing dateApr 26, 2016
Priority dateMar 28, 2012
Publication dateMar 27, 2018
Grant dateMar 27, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.

First claim

Opening claim text (preview).

What is claimed is: 1. A pharmaceutical composition comprising a compound according to Formula I: R′HN—(CH 2 ) x —NH—(CH 2 ) y —NH—CH 2 —R—CH 2 —NH—(CH 2 ) xx —NH—(CH 2 ) yy —NHR″  (I) wherein R is selected from the group consisting of anthracene, naphthalene, and benzene; wherein R′ and R″ are each independently an alkyl group; wherein x, xx, y, and yy are independently selected from the group consisting of 3 and 4; or a pharmaceutically acceptable salt thereof; and difluoromethylomithine (DFMO), at least one chemotherapeutic agent, or both. 2. The composition of claim 1 , wherein R′ and R″ are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, and butyl. 3. The composition of claim 2 , wherein R′ and R″ are each methyl. 4. The composition of claim 1 , wherein x, xx, y, and yy are each 4. 5. The composition of claim 1 , wherein x, xx, y, and yy are each 3. 6. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=anthracene. 7. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=naphthalene. 8. The composition of claim 1 , wherein R′ and R″=methyl, wherein x, xx, y, and yy are each 4, and wherein R=benzene. 9. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier. 10. A method for inhibiting polyamine transport in cells of a subject having an active polyamine transport system, the method comprising administering to the subject a composition of claim 1 in an amount effective to reduce polyamine transport in the cells. 11. The method of claim 10 , wherein the composition further comprises a pharmaceutically acceptable carrier. 12. The method of claim 10 , wherein R′ and R of Formula III are methyl and anthracene, respectively. 13. The method of claim 10 , wherein R′ and R of Formula III are methyl and naphthalene, respectively. 14. The method of claim 10 , wherein R′ and R of Formula III are methyl and benzene, respectively. 15. A method of inhibiting the growth of a cell, the method comprising contacting the cell with an effective amount of a composition of claim 1 such that the cell is targeted via its active polyamine transport system and its growth is inhibited. 16. A method for inhibiting polyamine transport in cells of a subject having an active polyamine transport system, the method comprising administering to the subject a composition in an amount effective to reduce polyamine transport in the cells, wherein the composition comprises a compound of the following formula: wherein R is selected from the group consisting of anthracene, naphthalene, and benzene; and wherein each R′ is independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, and butyl; or a pharmaceutically acceptable salt of said compound; and difluoromethylornithine (DFMO), at least one chemotherapeutic agent, or both.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title

  • C07C211/31Primary

    the six-membered aromatic ring being part of a condensed ring system formed by at least three rings · CPC title

  • Polyalkylene(poly)amines · CPC title

  • Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9926260B2 cover?
Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.
Who is the assignee on this patent?
Univ Central Florida Res Found Inc
What technology area does this patent fall under?
Primary CPC classification C07C211/31. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).